Overview

Total Hip Replacement Study With XRP4563 (Enoxaparin Sodium)

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is performed to confirm the optimal dose for THR (total hip replacement).
Phase:
Phase 3
Details
Lead Sponsor:
Sanofi
Treatments:
Enoxaparin
Enoxaparin sodium